# Nuevocor

> Nuevocor is a Singapore-founded, clinical-stage biotechnology company developing genetic medicines for cardiomyopathies driven by aberrant mechanobiology - the mechanical stresses that damage heart-muscle cells. Spun out of Singapore's A*STAR research agency in 2021, the company built a proprietary discovery engine called PrOSIA (Protein Organ Specific Interactome Analysis) to map the functional root causes of genetic heart disease. Its lead program, NVC-001, is an AAV-based gene therapy for LMNA-related dilated cardiomyopathy, an aggressive inherited heart condition with no targeted treatment. Nuevocor received FDA IND clearance for NVC-001 in June 2025 and has raised roughly US$80.6 million to date, including a US$45 million Series B in May 2025.

- **Founded:** 2021
- **Headquarters:** Singapore
- **Founders:** Yann Chong Tan (Co-Founder (former CEO; previously co-founded Atreca and served as Chief Innovation Officer at A*STAR's Genome Institute of Singapore)), Colin Stewart (Scientific Co-Founder (A*STAR researcher whose lamin/nuclear-envelope work underpins the lead program)), Brian Burke (Scientific Co-Founder (A*STAR researcher in nuclear-envelope and mechanobiology)), Yin Loon Lee (Co-Founder)
- **Team size:** Approximately 29 employees
- **Products:** NVC-001, PrOSIA Platform
- **Notable:** Received FDA IND clearance for NVC-001 in June 2025, its first-in-class gene therapy for LMNA-related dilated cardiomyopathy., Closed a US$45 million Series B in May 2025 co-led by Kurma Partners and Angelini Ventures., Raised roughly US$80.6 million in total funding since its 2021 founding.

## Products & services

- **NVC-001** — First-in-class AAV-based gene therapy for LMNA-related dilated cardiomyopathy (LMNA DCM). Designed to reduce aberrant mechanical forces on the cell nucleus and restore nuclear envelope integrity, a hallmark of the disease. Delivered as a one-time intravenous infusion. FDA IND cleared June 2025; Phase 1/2 trial planned for early 2026.
- **PrOSIA Platform** — Proprietary Protein Organ Specific Interactome Analysis platform that maps the functional root causes of genetic cardiomyopathies and identifies pathway-specific therapeutic targets across the 30+ mutations known to cause the disease, moving beyond conventional gene-replacement approaches.

## Achievements

- Received FDA IND clearance for NVC-001 in June 2025, its first-in-class gene therapy for LMNA-related dilated cardiomyopathy.
- Closed a US$45 million Series B in May 2025 co-led by Kurma Partners and Angelini Ventures.
- Raised roughly US$80.6 million in total funding since its 2021 founding.
- Built the proprietary PrOSIA mechanobiology discovery platform to address 30+ cardiomyopathy-causing mutations.
- Grew from an A*STAR research spinout to a three-continent clinical-stage company (Singapore, US, France).

## Latest updates

- **2026-04** — Dr. Monica Shah, MD, FACC appointed Chief Medical Officer.
- **2026-01** — Al Gianchetti appointed Chief Executive Officer as the company moves toward the clinic.
- **2025-06** — FDA cleared the IND for NVC-001, enabling a Phase 1/2 trial in LMNA-related dilated cardiomyopathy.
- **2025-05** — Closed US$45 million Series B financing co-led by Kurma Partners and Angelini Ventures.

## Links

- Website: https://nuevocor.com
- LinkedIn: https://www.linkedin.com/company/nuevocor

---

Profile page: https://yespress.io/nuevocor
Published by YesPress — https://yespress.io
Last updated: 2026-07-25